We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Product type
Topic
- Advertising (272)
- COVID-19 (163)
- Safety monitoring and information (96)
- Legislation (93)
- Compliance and enforcement (65)
- Manufacturing (52)
- Vaping hub (51)
- Labelling and packaging (35)
- Scheduling (national classification system) (27)
- Import and export (26)
- Medicinal cannabis hub (25)
- Sunscreens (16)
- Shortages and supply disruptions (14)
- Weight loss products (14)
- Committees and advisory bodies (9)
- Cosmetics (5)
- Unique Device Identification (UDI) hub (4)
- Clinical trials (3)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
98 result(s) found, displaying 1 to 25
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Media releasesWe are aware of misinformation that claims the COVID-19 mRNA vaccines are contaminated with excessive levels of DNA. This is not the case.
-
News articlesFollowing our Essential Principles presentations on 11-12 September 2024, we have collated questions asked into themes to simplify finding information of relevance to you.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Regulatory decision noticesVoluntary cancellation of AstraZeneca COVID-19 vaccine: Vaxzevria
-
Regulatory decision noticesWe've granted a labelling exemption for the COVID-19 Vaccine, Pfizer (raxtozinameran), under the current Poisons Standard.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
News articlesTo help sponsors and manufacturers transition to new manufacturer evidence.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
News articlesTransition period for accepting ISO 13485 ends 26 May 2023.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
News articlesThe TGA will recognise the extended transition for the European Union Medical Device Regulation (EU MDR).
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThe TGA has approved Moderna Australia’s application to transition its COVID-19 vaccine, SPIKEVAX (elasomeran), from provisional to full registration.